INVO Fertility, Inc. (INVO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading as INVO Fertility, Inc.) on November 9, 2020, reporting events that occurred on November 8, 2020. The company is incorporated in Nevada and its common stock trades on the OTCMKTS under the symbol "INVO".
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The Board of Directors expanded its size from five (5) to seven (7) members. Jeffrey J. Segal, M.D., was appointed as a new director to fill one of the vacancies created by this expansion. Following this appointment, one vacancy on the Board remains unfilled.
Management Commentary and Risks
Dr. Segal brings significant experience in healthcare and legal sectors. He is a board-certified neurosurgeon, the founder and CEO of Medical Justice Services Inc., and a partner at the Byrd Adatto Law Firm. His background includes founding companies focused on CNS disorders and physician scheduling solutions. No specific risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Board size increased to 7 directors, with 1 vacancy remaining.
- New director Jeffrey J. Segal, M.D., has a background in neurosurgery, healthcare law, and biotech startups.
- No financial performance data or guidance is provided in this specific filing.
- Verify the timeline for filling the remaining board vacancy.